The effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on ischemic stroke and the possible underlying mechanisms

Int J Neurosci. 2023 Feb;133(2):176-185. doi: 10.1080/00207454.2021.1897588. Epub 2021 Mar 26.

Abstract

Purpose: As of November 28, 2020, COVID-19 has been reported in 220 countries with 61,036,793 confirmed cases and 1,433,316 confirmed deaths; countries became vigilant around the world. In addition to SARS-CoV-2 causing pneumonia, many studies have reported ischemic stroke in patients with COVID-19. This article describes the effects and possible underlying mechanisms of SARS-CoV-2 on ischemic stroke.Materials and methods: A literature search was performed using PubMed, Web of Science, and other COVID-dedicated databases and the combination of the keywords 'SARS-CoV-2', 'COVID-19' and 'ischemic stroke' up to November 28, 2020.Results: SARS-CoV-2 invades the host through angiotensin converting enzyme 2 (ACE2). ACE2 is expressed not only in the lungs, but also in the brain and vascular endothelial cells. SARS-CoV-2 infection might cause direct vascular disease or enhance the immunogenic thrombosis environment through several mechanisms. SARS-CoV-2 infection can modulate the host immune response and can cause inflammation, coagulation disorders, renin angiotensin system disorders, hypoxia, and stress disorders, which may lead to the occurrence of ischemic stroke.Conclusions: Some patients with COVID-19 can develop ischemic stroke. Ischemic stroke has a high risk of causing disability and is associated with a high mortality rate. It is hoped that when medical staff treat patients with COVID-19, they would pay attention to the occurrence of ischemic stroke to improve the prognosis of patients with COVID-19.

Keywords: COVID-19; SARS-CoV-2; coagulation disorders; hypoxia; inflammation; ischemic stroke; renin − angiotensin system; stress.

MeSH terms

  • Angiotensin-Converting Enzyme 2
  • COVID-19* / complications
  • Endothelial Cells
  • Humans
  • Ischemic Stroke* / complications
  • Peptidyl-Dipeptidase A
  • SARS-CoV-2

Substances

  • Angiotensin-Converting Enzyme 2
  • Peptidyl-Dipeptidase A

Grants and funding

This work was supported by the ‘Six Talent Peaks’ project of Jiangsu Province under Grant (No. WSW-246).